Burning Rock Biotech Limited
BNR
Rank in Stocks
#27916
Headquartered in Guangzhou, China, and established in 2014, Burning Rock... Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Share Price
$12.39
Last synced: 2026-11-09
Market Cap
$13.07M
Change (1 day)
-7.68%
Change (1 year)
1.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Burning Rock Biotech Limited (BNR)
Category
Healthcare
Operating Margin for Burning Rock Biotech Limited (BNR)
Operating Margin as of November 2026 TTM: -12.99%
According to Burning Rock Biotech Limited's latest financial reports, its current operating margin (TTM) is -12.99%. At the end of 2025 the company had an operating margin of -10.16%.
Operating Margin history for Burning Rock Biotech Limited from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -12.99% | 27.85% |
| 2025 | -10.16% | -85.34% |
| 2024 | -69.32% | -44.34% |
| 2023 | -124.54% | -28.45% |
| 2022 | -174.07% | 10.91% |
| 2021 | -156.94% | 63.60% |
| 2020 | -95.93% | 116.55% |
| 2019 | -44.30% | -42.67% |
| 2018 | -77.27% | -28.93% |
| 2017 | -108.73% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -101.38% |
US
|
|
| 20.38% | -101.57% |
US
|
|
| 43.02% | -103.31% |
CN
|
|
| 32.03% | -102.47% |
US
|
|
| 22.23% | -101.71% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Burning Rock Biotech Limited's operating margin
What is Burning Rock Biotech Limited's operating margin?
Burning Rock Biotech Limited's operating margin is -12.99%, as of Nov 2026.
What was Burning Rock Biotech Limited's operating margin in 2025?
In 2025, Burning Rock Biotech Limited's operating margin was -10.16%, compared with -69.32% in 2024.
How has Burning Rock Biotech Limited's operating margin changed since 2020?
From 2020 to 2025, Burning Rock Biotech Limited's operating margin was highest in 2025 (-10.16%) and lowest in 2022 (-174.07%).
How does Burning Rock Biotech Limited's operating margin compare with similar companies?
Burning Rock Biotech Limited's operating margin (-12.99%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.